Lund, Sweden, 29th of December 2017 - Xintela AB (publ) today announced the company has licensed antibody technology for the development of human antibodies in diagnostics and therapy. The antibodies, directed to Xintela's markers integrin α10β1 och integrin α11β1, are already adapted for human use. This means that Xintela saves both time and money and that Xintela's cancer products can be tested earlier in clinical trials.
“These antibodies, I have worked with and developed for several years at my previous company, Cartela. I addition, the antibodies are human and therefore already adapted for human use. This means that we will save both time and money in our preclinical work and Xintela's ADC-based products can be tested earlier in clinical trials,” says Xintela’s CEO Evy Lundgren-Åkerlund.
As previously reported, Xintela has shown that mouse antibodies directed toward integrin α10β1 and linked to a cellular toxin had a killing effect on human gliobloma cells both in vitro and in vivo. With these findings, Xintela was able to demonstrate that treatment of glioblastoma cells with an Antibody-Drug-Conjugate (ADC) based on an integrin α10β1-antibody is a new, promising treatment concept for this aggressive brain tumor.
“It is advantageous for Xintela to have access to human antibodies that are well-characterized and have already shown promising results both on cells and in animal models. Primarily, we will develop the antibodies for the treatment of glioblastoma, but we will also evaluate the antibodies in other cancer forms to build a broader platform for cancer therapy and diagnostics,” says Evy Lundgren-Åkerlund.
Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
223 81 Lund
For investor relations and media questions, please contact:
Mårten Svanberg, Laika Consulting
Tel: 070-362 70 05
Xintela develops medical products for regenerative medicine and cancer based on its proprietary marker technology, XINMARK®. Xintela uses the technology to select and assure the quality of mesenchymal stem cells for the treatment of cartilage damage and osteoarthritis. In a study on horses, the company has shown that stem cells are safe to use and that they have a positive effect on the articular cartilage and the underlying bone after an injury. In addition, Xintela has developed an assay XACTTM for the quality control chondrocyte preprations in cell therapy of cartilage. XINMARK® is also used for the development of an antibody-based treatment (Antibody Drug Conjugate, ADC) against glioblastoma, the most common and aggressive form of brain tumors in adults. Positive preclinical results from cell studies and animal model have shown that the antibody has a killing effect on glioblastoma cells and thus has confirmed the concept. Xintela is listed on Nasdaq First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.
This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the above contact, for publication on the 29th of December 2017, at 08.50 CET.
Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.
Dr. Marcus Keep comments on Xintelas glioblastoma project.
Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.
Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.
In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.
See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.
See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).
See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.
Investor presentation from Lund - Jan 27
Interview with Xintelas CEO